Compare Stocks: MSCI, LLY, and HIMS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HIMS Hims & Hers Health	$27.66 -0.6%	$31.79	$13.74 ▼ $65.30	$6.45B	2.42	25.23 million shs	7.14 million shs
LLY Eli Lilly and Company	$1,147.06 -1.1%	$1,192.90	$712.05 ▼ $1,292.65	$1.08T	0.5	3.07 million shs	2.22 million shs
MSCI MSCI	$572.27 -0.4%	$579.21	$501.08 ▼ $644.77	$41.60B	1.22	644,549 shs	476,868 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HIMS Hims & Hers Health	-3.07%	-12.20%	-13.44%	+5.77%	-37.60%
LLY Eli Lilly and Company	+0.04%	-1.19%	+4.06%	+2.46%	+57.69%
MSCI MSCI	+2.27%	+1.10%	+0.49%	-6.73%	+4.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HIMS Hims & Hers Health	$27.66 -0.6%	$31.79	$13.74 ▼ $65.30	$6.45B	2.42	25.23 million shs	7.14 million shs
LLY Eli Lilly and Company	$1,147.06 -1.1%	$1,192.90	$712.05 ▼ $1,292.65	$1.08T	0.5	3.07 million shs	2.22 million shs
MSCI MSCI	$572.27 -0.4%	$579.21	$501.08 ▼ $644.77	$41.60B	1.22	644,549 shs	476,868 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HIMS Hims & Hers Health	-3.07%	-12.20%	-13.44%	+5.77%	-37.60%
LLY Eli Lilly and Company	+0.04%	-1.19%	+4.06%	+2.46%	+57.69%
MSCI MSCI	+2.27%	+1.10%	+0.49%	-6.73%	+4.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HIMS Hims & Hers Health	2.19	Hold	$32.50	17.50% Upside
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,292.18	12.65% Upside
MSCI MSCI	3.08	Buy	$709.50	23.98% Upside

Current Analyst Ratings Breakdown

Latest MSCI, LLY, and HIMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Buy
8/26/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/24/2026	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$27.00 ➝ $32.00
8/21/2026	HIMS Hims & Hers Health	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $35.00
8/11/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	HIMS Hims & Hers Health	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$25.00 ➝ $26.00
8/11/2026	HIMS Hims & Hers Health	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$25.00 ➝ $30.00
8/11/2026	HIMS Hims & Hers Health	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$21.00 ➝ $28.00
8/11/2026	HIMS Hims & Hers Health	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$35.00 ➝ $33.00
8/11/2026	HIMS Hims & Hers Health	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$30.00 ➝ $32.00
8/11/2026	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $42.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HIMS Hims & Hers Health	$2.35B	2.75	$0.81 per share	34.27	$1.39 per share	19.90
LLY Eli Lilly and Company	$65.18B	16.57	$24.86 per share	46.15	$35.99 per share	31.87
MSCI MSCI	$3.13B	13.27	$21.52 per share	26.59	($36.99) per share	-15.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HIMS Hims & Hers Health	$128.37M	-$0.63	N/A	55.32	N/A	-5.51%	-6.51%	-1.20%	11/9/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	38.49	25.01	1.44	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
MSCI MSCI	$1.20B	$18.28	31.31	25.60	2.14	40.74%	-55.19%	24.90%	10/20/2026 (Estimated)

Latest MSCI, LLY, and HIMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	HIMS Hims & Hers Health	-$0.0498	-$0.37	-$0.3202	-$0.37	$698.90 million	$753.21 million
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
7/21/2026	Q2 2026	MSCI MSCI	$4.99	$4.94	-$0.05	$4.69	$870.71 million	$867.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.60%	+15.18%	23.22%	11 Years
MSCI MSCI	$8.20	1.43%	+19.78%	44.86%	11 Years

Latest MSCI, LLY, and HIMS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
7/20/2026	MSCI MSCI	quarterly	$2.05	1.44%	8/14/2026	8/14/2026	8/28/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HIMS Hims & Hers Health	4.21	0.93	0.87
LLY Eli Lilly and Company	1.41	1.35	1.00
MSCI MSCI	N/A	0.89	0.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HIMS Hims & Hers Health	63.52%
LLY Eli Lilly and Company	82.53%
MSCI MSCI	89.97%

Insider Ownership

Company	Insider Ownership
HIMS Hims & Hers Health	11.76%
LLY Eli Lilly and Company	0.14%
MSCI MSCI	3.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HIMS Hims & Hers Health	2,442	233.31 million	205.88 million	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
MSCI MSCI	6,268	72.70 million	69.97 million	Optionable

MSCI, LLY, and HIMS Headlines

Recent News About These Companies

Why Adani Energy fell 10% despite expected MSCI inflows: GQG sold nearly 20 million shares

September 4 at 12:57 PM | cnbctv18.comC

India's Swiggy pares gains as its shares exit MSCI indexes

September 4 at 12:57 PM | msn.com

Swiggy sees 4% equity change hands in block deals; shares gain 2.5%

September 4 at 9:31 AM | economictimes.indiatimes.com

Global Market Today: Asian stocks rise as Fed rate-hike bets ease

September 3 at 9:50 PM | economictimes.indiatimes.com

Swiggy shares fall 2%, down for 3rd session, as MSCI set to remove stock from Global Standard Indexes from September 7

September 3 at 8:14 PM | msn.com

MSCI to Participate in Barclays Annual Global Financial Services Conference

September 3 at 8:41 AM | businesswire.com

Swiggy share price under pressure after NSDL red flag, MSCI, FTSE shake-up - What's next for investors? Should you BUY, SELL or HOLD?

September 3 at 8:35 AM | msn.com

Swiggy Shares in Focus After Major MSCI Index Move: What Triggered the Decision?

September 3 at 3:35 AM | outlookmoney.comO

MSCI Index India rebalancing impact | Swiggy share price falls for second day in a row

September 3 at 3:35 AM | livemint.com

Swiggy shares in focus as MSCI to remove stock from Global Standard Indexes from September 7

September 2 at 11:50 PM | economictimes.indiatimes.com

Swiggy shares fall over 4% on MSCI index exclusion fears

September 2 at 10:34 PM | newsbytesapp.comN

Swiggy to be removed from MSCI Standard and Mid Cap indices from Sept 7

September 2 at 10:34 PM | cnbctv18.comC

Swiggy to exit MSCI Global Standard and Mid Cap indexes

September 2 at 10:34 PM | newsbytesapp.comN

MSCI to drop Swiggy from global indices on September 7

September 2 at 9:31 PM | economictimes.indiatimes.com

Baron Global Opportunity Fund’s Q2 2026 Investor Letter

September 2 at 11:10 AM | insidermonkey.com

Here’s What Weighed on Nu Holdings (NU) in Q2

September 2 at 11:10 AM | insidermonkey.com

What Makes DPC Holdings Limited (DPC) an Attractive Bet?

September 2 at 11:10 AM | insidermonkey.com

MSCI to delete Swiggy from standard indices on foreign ownership limit breach risk

September 2 at 10:10 AM | economictimes.indiatimes.com

Hotchkis & Wiley Global Value Fund’s Q2 2026 Investor Letter

September 2 at 8:51 AM | insidermonkey.com

BNP Paribas said to handle half of India’s record MSCI trades

September 2 at 7:51 AM | economictimes.indiatimes.com

MSCI Inc $MSCI Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 1 at 5:43 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MSCI, LLY, and HIMS Company Descriptions

Hims & Hers Health NYSE:HIMS

$27.66 -0.16 (-0.58%)

As of 03:58 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company NYSE:LLY

$1,147.06 -12.54 (-1.08%)

As of 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

MSCI NYSE:MSCI

$572.27 -2.38 (-0.41%)

As of 03:58 PM Eastern

MSCI Inc., together with its subsidiaries, provides critical decision support tools and solutions for the investment community to manage investment processes worldwide. The Index segment provides indexes for use in various areas of the investment process, including indexed financial product, such as ETFs, mutual funds, annuities, futures, options, structured products, and over-the-counter derivatives; performance benchmarking; portfolio construction and rebalancing; and asset allocation, as well as licenses GICS and GICS Direct. The Analytics segment offers risk management, performance attribution and portfolio management content, application, an integrated view of risk and return service, and an analysis of market, credit, liquidity, counterparty, and climate risk across asset classes; managed services, including consolidation of client portfolio data, review and reconciliation of input data and results, and customized reporting; and HedgePlatform to measure, evaluate, and monitor the risk of hedge fund investments. The ESG and Climate segment provides products and services that help institutional investors understand how ESG impacts the long-term risk and return of their portfolio and individual security-level investments; and data, ratings, research, and tools to help investors navigate increasing regulation. The All Other Private Assets segment includes real estate and infrastructure data, benchmarks, return-analytics, climate assessments and market insights; business intelligence to real estate owners, managers, developers, and brokers; and offers investment decision support tools for private capital. The Private Capital Solutions segment offers tools to help private asset investors across mission-critical workflows, such as sourcing terms and conditions, evaluating operating performance, managing risk and other activities supporting private capital investing. MSCI Inc. was incorporated in 1998 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MSCI, LLY, and HIMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MSCI, LLY, and HIMS Earnings

Compare Dividends

Latest MSCI, LLY, and HIMS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MSCI, LLY, and HIMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MSCI, LLY, and HIMS Company Descriptions

Hims & Hers Health NYSE:HIMS

Eli Lilly and Company NYSE:LLY

MSCI NYSE:MSCI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MSCI, LLY, and HIMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MSCI, LLY, and HIMS Earnings

Compare Dividends

Latest MSCI, LLY, and HIMS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MSCI, LLY, and HIMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MSCI, LLY, and HIMS Company Descriptions

Hims & Hers Health NYSE:HIMS

Eli Lilly and Company NYSE:LLY

MSCI NYSE:MSCI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools